Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RNK05047 |
| Synonyms | |
| Therapy Description |
RNK05047 is a BRD4-chaperone-mediated protein degrader (BRD4-CHAMP), which binds to BRD4 and targets it for degradation via interaction with HSP90, potentially resulting in antitumor activity (European Journal of Cancer 174 (2022): S27). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RNK05047 | RNK-05047|RNK 05047 | RNK05047 is a BRD4-chaperone-mediated protein degrader (BRD4-CHAMP), which binds to BRD4 and targets it for degradation via interaction with HSP90, potentially resulting in antitumor activity (European Journal of Cancer 174 (2022): S27). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05487170 | Phase Ib/II | RNK05047 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | Recruiting | USA | 1 |